Organization
The Ohio State University Comprehensive Cancer Center, Columbus, OH
3 abstracts
Abstract
Selpercatinib in non-MTC, RET-mutated tumors: Efficacy in MEN-associated and other tumors.Org: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy, Royal North Shore Hospital, St. Leonards, NSW, Australia, Multidisciplinary Oncology & Therapeutic Innovations, Hôpitaux Universitaires de Marseille Timone, Marseille, France, Department of Respiratory Medicine, Nagoya University Graduate school of Medicine, Nagoya, Japan, The Ohio State University Comprehensive Cancer Center, Columbus, OH,
Abstract
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.Org: Winship Cancer Institute of Emory University, Atlanta, GA, University of Alabama at Birmingham, Birmingham, AL, University of California, San Francisco, San Francisco, CA, University of California, San Diego, La Jolla, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).Org: The Ohio State University Comprehensive Cancer Center, Columbus, OH, Institutul Oncologic Prof Dr Ion Chiricută and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, SF Nectarie Oncology Center, Craiova, Romania, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, L’institut du Thorax, Nantes, France,